Preclinical Imaging (In-VIVO) Market Overview
The Preclinical Imaging (In-VIVO) Market was valued at USD 1.16 Billion in 2025 and is projected to reach USD 1.62 Billion by 2032, growing at a CAGR of 4.9% during 2026–2032, with North America holding the largest share.
Primary Drivers
- Rising global pharmaceutical and biotech R&D investment, particularly in oncology and CNS drug development, is driving demand for preclinical in-vivo imaging systems.
- Growth in academic and government-funded life sciences research is expanding installed base demand for multi-modality imaging platforms (PET, SPECT, MRI, optical).
- Increasing adoption of non-invasive, longitudinal imaging techniques that reduce animal usage and improve data quality is reinforcing preclinical imaging's role in drug development pipelines.
Primary Challenges
- High capital cost of multi-modality preclinical imaging systems limits adoption among smaller research institutions and academic labs.
- Growing ethical and regulatory pressure to reduce animal testing (3Rs principles) creates long-term uncertainty for animal-based preclinical imaging demand.
- Technical complexity and need for specialized personnel to operate and interpret advanced imaging systems raise operating costs for research facilities.
This report includes a dedicated chapter covering supply chain exposure, export controls, sanctions risk, and regulatory shifts affecting Preclinical Imaging (In-VIVO) Market.
Preclinical Imaging (In-VIVO) Market Strategic Outlook
Preclinical imaging is medical process of visualization of living animals for purpose of research, such as new medical procedure and drug development. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes.
Growth trajectory, 2026–2032
How this market is covered
Revenue split by type
Revenue by end use
In application aspect, vivo imaging is increasingly deployed across the drug development process, with applicability in target identification, compound optimization and pre-Phase I studies. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. The key diseases/therapeutic areas targeted with in vivo preclinical imaging by survey respondents were oncology/cancer (70% targeting). This was followed by inflammatory disease/autoimmune (36% targeting), neurology / CNS / neurodegeneration/ pain (32% targeting) and then cardiovascular (25% targeting)
Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. The most suitable modalities for small-animal in vivo imaging applications are based on nuclear medicine techniques (essentially, positron emission tomography [PET] and single photon emission computed tomography [SPECT]), optical imaging (OI), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy imaging (MRSI), and ultrasound.
Geographically, Preclinical Imaging (In-VIVO) Market categorised in North America, Europe, China, Japan, South East Asia, India and Rest of World. North America holds the highest sale volume of market. Increased in Pharmaceutical research, new development in biotechnology, government support for various research work and advancement in technology are the prime factor driving the Preclinical Imaging (In-VIVO) Market globally. Europe and Asia –Pacific market is expected to grow at higher CAGR in forecasted years. African market expected to grow at lower rate while Middle East and South American market is expected to show constant growth rate.
Preclinical Imaging (In-VIVO) Market: Techniques Type
- MRI (Magnetic Resonance Imaging)
- PET (Positron Emission Tomography)
- SPECT (Single Photon Emission Computed Tomography)
- Micro-CT (Micro Computed Tomography)
- Optical imaging and Magnetic particle (MPI)
Preclinical Imaging (In-VIVO) Market: Vessel Type
- Oncology
- Neurology
- Cardiology
- Inflammation
- Infectious diseases
- Cancer research
- Functional and Anatomical Neuroimaging
- Orthopedics
- Cardiac imaging
- Stroke models
Preclinical Imaging (In-VIVO) Market : Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study consists of following key players in Preclinical Imaging (In-VIVO) Market:
- PerkinElmer
- Bruker Corporation
- FUJIFILM Holdings
- Mediso
- MILabs B.V.
- MR Solutions
- Aspect Imaging
- LI-COR Biosciences
- Trifoil Imaging
- Miltenyi Biotec
Geographical analysis of Preclinical Imaging (In-VIVO) Market:
-
North America
- U.S.A
- Canada
- Europe
- France
- Germany
- Spain
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South East Asia
- Latin America
- Brazil
- Middle East and Africa
Diagnostic Imaging & Measurement Devices Landscape
Report Coverage
| Parameter | Details |
|---|---|
| Base Year | 2025 |
| Historical Data | 2020 – 2025 |
| Forecast Period | 2026 – 2032 |
| Base Year Value | USD 1.16 Billion |
| Forecast Value | USD 1.62 Billion |
| CAGR | 4.9% |
| Regional Scope | North America · Europe · Asia-Pacific · Latin America · MEA · RoW |
Frequently Asked Questions
Preclinical Imaging (In-VIVO) Market was valued at USD 1.16 Billion in 2025 and is estimated to reach USD 1.62 Billion by 2032.
Preclinical Imaging (In-VIVO) Market is projected to grow at a CAGR of 4.9% during 2025–2032.
Preclinical Imaging (In-VIVO) Market is dominated by the MRI (Magnetic Resonance Imaging) segment and the North America region holds the highest market share in 2025.
Some of the top key players in the Preclinical Imaging (In-VIVO) Market are PerkinElmer, Bruker Corporation, FUJIFILM Holdings, Mediso, MILabs B.V., MR Solutions, Aspect Imaging, LI-COR Biosciences, Trifoil Imaging, Miltenyi Biotec.
1. Rising global pharmaceutical and biotech R&D investment, particularly in oncology and CNS drug development, is driving demand for preclinical in-vivo imaging systems. 2. Growth in academic and government-funded life sciences research is expanding installed base demand for multi-modality imaging platforms (PET, SPECT, MRI, optical). 3. Increasing adoption of non-invasive, longitudinal imaging techniques that reduce animal usage and improve data quality is reinforcing preclinical imaging's role in drug development pipelines.
Yes. The report includes a dedicated section on geopolitical risk factors and their impact on supply chains, pricing, and regional demand dynamics.